Diabetes therapies take new approach
Use substances made by the body
WASHINGTON - Two experimental treatments suggest new directions for treating diabetes, both using compounds already made by the body, researchers in the United States reported yesterday.
One of the two studies suggests that some current treatments for autoimmune diseases such as Crohn's disease, which affects the gastrointestinal tract, may be taking the wrong approach and doing active harm to some patients.
The two reports, published in the Proceedings of the National Academy of Sciences, each aim to correct some of the things that go wrong to cause type 1 diabetes, which is caused when immune cells mistakenly destroy the cells in the pancreas that make insulin.
The International Diabetes Federation estimates that 230 million people globally have diabetes, and about 10 percent of these have type 1. Patients are usually diagnosed at a young age and must carefully measure blood sugar levels and take insulin for life. There is no cure.
Dr. Denise Faustman and colleagues at Massachusetts General Hospital and Harvard Medical School in Boston tested a cheap, generic drug used to prevent tuberculosis, called bacillus Calmette-Guerin.
Faustman said bacillus Calmette-Guerin temporarily elevates levels of an immune system protein called tumor necrosis factor. Earlier studies showed raising the tumor necrosis factor in mice can cure them of a condition resembling human diabetes.
"If you are a mouse, we have got you covered. But the ultimate goal is people," Faustman said.
Her team showed that people with type-1 diabetes have certain numbers of abnormal immune system cells called T-cells. These attack and destroy the pancreatic tissues that normally make insulin.
The tests on blood from 675 people with diabetes and 512 healthy people showed the diabetics had some CD8 "killer" T-cells that could be killed by the tumor necrosis factor or bacillus Calmette-Guerin.
"Good" T-cells were not killed by the treatment, they wrote.
The same team is testing bacillus Calmette-Guerin at very low doses in a Phase I clinical safety trial in a few volunteers. "Now we have these T-cell markers from blood . . . so we can know within weeks if we are getting rid of the bad T-cells," Faustman said.
She said her study suggests that anti-tumor necrosis factor therapies such as etanercept, sold by Wyeth and
A second team, at the University of Texas Southwestern Medical Center in Dallas, took a different tack, using a hormone called leptin.
Roger Unger of the Dallas medical center and colleagues used gene therapy to treat mice with damaged pancreases that made no insulin at all and were dying. They used a virus to carry in genes for leptin, which in turn caused their livers to pump out huge levels of the hormone.